Ultimately, the clinical importance of this study lies in the lack of head-to-head clinical trials of anti-PD-1 and anti-PD-L1 that allow us to compare the efficacy and safety of both drugs, thus deciding the best therapeutic option for NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.